No-Washout Trait Check: Retinal Confirmation of ADHD in Medicated Kids
A quick eye test for children on ADHD medication to confirm their diagnosis without needing to stop their medicine first.
A quick retinal (ERG) check for children already taking ADHD medication who need reassessment or a second opinion, showing whether the ADHD-typical retinal response is still present — because the measure appears unaffected by stimulants, no medication washout is needed.
Concept
A point-of-care retinal (ERG) b-wave check designed for one specific visit: the reassessment or second opinion of a child or teenager who is already taking stimulant medication. Today that visit leans on parent/teacher rating scales and clinical history, because behavioral and computerized measures are confounded by treatment and formal medication washouts are disruptive and rarely done in practice. The product is a 15-minute light-adapted ERG (nine flashes up to 1.204 log photopic cd.s.m−2) with a readout that reports whether the child's b-wave amplitude sits in the elevated, ADHD-consistent band (~37 μV vs ~28 μV in controls) and whether the b-wave time-to-peak falls in the faster ADHD range — i.e., whether the physiological trait signature is present despite ongoing medication. The report is explicitly framed as supporting evidence for the clinician, not a diagnosis. Because the medication-stability finding rests on a small tested subset (5 medicated participants), the product ships as a pilot offering with a built-in registry that accumulates medicated-vs-unmedicated ERG data at every visit, turning routine follow-ups into the validation dataset.
Why now
The source study [0] found that stimulant medication (methylphenidate) did not significantly impact the ERG measures in the ADHD participants tested, while the ADHD retinal signature itself was robust: elevated b-wave amplitudes (37.2 ± 10.3 μV vs 28.2 ± 8.6 μV in controls at 1.204 log phot cd.s.m−2), elevated PhNR responses, and faster b-wave time-to-peak (30.6 ± 1.1 ms). Mechanistically this is coherent — the b-wave is generated by glutamate/GABA synaptic activity in the retina, not the dopaminergic targets of stimulants — so the marker plausibly tracks the trait rather than the treatment state. That combination (a robust group signature plus apparent insensitivity to the most common ADHD medication) is exactly what a no-washout reassessment tool needs, and nothing in today's ADHD toolkit (rating scales, computerized attention tests) offers it, since all of those are behavior-derived and treatment-sensitive. The limitation is explicit and sized into the product: medication stability was observed in only 5 participants, so the claim is framed as preliminary evidence, confirmed as the tool is deployed.
Written by GLM · 10 Oct 2026
AI assessment
A clever application of ERG that solves the 'washout' problem in ADHD reassessment, though it relies on a very thin evidence base for medication stability.
- Evidence strength 2/5
- While the ADHD retinal signature is well-supported in the paper, the core value proposition—that stimulants don't affect the b-wave—is based on only 5 participants, which is statistically insufficient for a clinical claim.
- Market pull 4/5
- There is a genuine clinical pain point in ADHD reassessment where behavioral markers are confounded by medication, creating a strong pull for an objective, non-invasive physiological marker.
- Novelty & moat 2/5
- This is a direct variant of the 'B-Wave Split' idea, shifting the use case from differential diagnosis (ADHD vs ASD) to medication-stable reassessment using the same mechanism.
- Feasibility 3/5
- ERG hardware exists, but translating a lab-based Troland protocol into a 'point-of-care' 15-minute clinical tool requires significant engineering and regulatory hurdles.
- Wedge clarity 5/5
- The 'no-washout reassessment' is a sharp, specific wedge that targets a precise moment of clinical uncertainty.
- Simplicity / focus 5/5
- The idea is focused on a single test for a single specific clinical event, avoiding platform creep.
Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Qbtechcompany
Sells objective ADHD testing (QbTest) into clinics, but its measures are behavior-derived and treatment-sensitive; a stimulant-independent retinal trait readout extends its objective-testing line to the medicated-reassessment visit.
- NYU Langone Health Child Study Centerorganization
Large pediatric ADHD service that regularly reassesses children already on stimulants; a no-washout objective check fills a real gap left by treatment-confounded rating scales.
- Cincinnati Children's Hospital Medical Centerorganization
Runs a major pediatric ADHD clinical and research program that follows thousands of medicated children; an objective trait check at routine visits supports continuity of care and second opinions without medication holidays.
- Seattle Children's Hospitalorganization
Its ADHD program manages long-term stimulant treatment in children and teens; a quick physiological trait check at follow-up visits adds objective evidence where behavioral measures are confounded by treatment.
Research it builds on
- The electroretinogram b-wave amplitude: a differential physiological measure for Attention Deficit Hyperactivity Disorder and Autism Spectrum DisorderIrene Lee, David Skuse, Paul A. Constable et al. · 2022 · 44 citationsAll ideas from this paper →